ARCA biopharma Inc (ABIO)
3.58
+0.10
(+2.87%)
USD |
NASDAQ |
Apr 26, 16:00
3.58
0.00 (0.00%)
After-Hours: 17:39
ARCA biopharma Research and Development Expense (Quarterly): 0.047M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.047M |
| September 30, 2023 | 0.322M |
| June 30, 2023 | 0.254M |
| March 31, 2023 | 0.39M |
| December 31, 2022 | 0.061M |
| September 30, 2022 | 1.024M |
| June 30, 2022 | 1.485M |
| March 31, 2022 | 2.179M |
| December 31, 2021 | 3.941M |
| September 30, 2021 | 3.438M |
| June 30, 2021 | 3.577M |
| March 31, 2021 | 2.876M |
| December 31, 2020 | 3.204M |
| September 30, 2020 | 1.051M |
| June 30, 2020 | 0.372M |
| March 31, 2020 | 0.365M |
| December 31, 2019 | 0.384M |
| September 30, 2019 | 0.347M |
| June 30, 2019 | 0.44M |
| March 31, 2019 | 0.662M |
| December 31, 2018 | 0.625M |
| September 30, 2018 | 0.74M |
| June 30, 2018 | 1.154M |
| March 31, 2018 | 1.72M |
| December 31, 2017 | 2.834M |
| Date | Value |
|---|---|
| September 30, 2017 | 3.488M |
| June 30, 2017 | 4.508M |
| March 31, 2017 | 3.246M |
| December 31, 2016 | 3.121M |
| September 30, 2016 | 3.72M |
| June 30, 2016 | 2.913M |
| March 31, 2016 | 2.594M |
| December 31, 2015 | 1.893M |
| September 30, 2015 | 1.716M |
| June 30, 2015 | 1.747M |
| March 31, 2015 | 1.707M |
| December 31, 2014 | 1.582M |
| September 30, 2014 | 1.335M |
| June 30, 2014 | 1.40M |
| March 31, 2014 | 1.308M |
| December 31, 2013 | 1.787M |
| September 30, 2013 | 0.714M |
| June 30, 2013 | 0.246M |
| March 31, 2013 | 0.181M |
| December 31, 2012 | 0.191M |
| September 30, 2012 | 0.156M |
| June 30, 2012 | 0.322M |
| March 31, 2012 | 0.422M |
| December 31, 2011 | 0.595M |
| September 30, 2011 | 0.533M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.047M
Minimum
Dec 2023
3.941M
Maximum
Dec 2021
1.356M
Average
0.44M
Median
Jun 2019
Research and Development Expense (Quarterly) Benchmarks
| Shockwave Medical Inc | 42.32M |
| Asensus Surgical Inc | 8.614M |
| Glaukos Corp | 39.06M |
| Helius Medical Technologies Inc | 0.65M |
| Perspective Therapeutics Inc | 6.08M |